Concerns Over Alleged Lapses By Sun Fading?
Executive Summary
Early indications that a whistleblower’s allegations of certain serious irregularities by Sun Pharma may not hold water lifted its shares, though it remains unclear if the issue stands completely closed.
You may also be interested in...
Ex-Sun Employee Alleges Reprisal For Opposing US Off-Label Practices
A Sun Pharma executive dismissed earlier this year has claimed retaliation by the company after she objected to the Indian firm’s alleged off-label marketing practices. Sun refutes the allegations and vows to vigorously defend itself, while experts suggest a settlement may be the way forward.
India’s Sun Sees Specialty Spend Checking Profit Growth
India’s biggest generics company cautions that investments to ramp up its specialty business are expected to constrain profit growth over the near term, as a one-off charge cuts fourth-quarter income in half.
Sun Firefights Governance Concerns
Sun has promised to implement certain changes to address corporate governance concerns that have riled investors, including “unwinding” a loan transaction and doing away with a controversial related party arrangement for domestic sales. But will that be enough for markets to "forget" allegations of lapses or "re-rate" the firm any time soon?